Global Polycystic Ovary Syndrome (PCOS) is a medical condition where the women of reproductive age suffer from hormonal disorders. This is due to an increase in levels of male hormones in the body which leads to an irregular menstrual cycle. Women experience symptoms such as irregular menstrual cycle, increase in facial hair growth, acne, thinning hair or hair loss on the scalp, weight gain, darkening of skin and others. Polycystic Ovary Syndrome (PCOS) is caused due to high levels of androgens, excess insulin, low-grade inflammation, cysts in the ovaries, and genetic disorders.

The polycystic ovarian syndrome market is expected to witness tremendous growth owing to the rising prevalence of polycystic ovarian syndrome. According to the Centers for Disease Control and Prevention, approximately 5 million women of reproductive age suffer from the polycystic ovarian syndrome.

Other key factors such as the growing obesity among women, rising prevalence of diabetes, increasing hormonal disorders in women, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, and others are contributing towards the growth of the market. Diabetes is another risk factor that leads to the development of the polycystic ovarian syndrome. Such factors contribute to polycystic ovarian syndrome among women.

However, factors such as side effects associated with drugs such as weight gain, cardiovascular risks, increase insulin resistance, abnormal glucose tolerance, and thromboembolic events are expected to restrict the market growth during the forecast period.

Segmentation

The global polycystic ovarian syndrome market is segmented on the basis of diagnosis, treatment, and end-user. The polycystic ovarian syndrome market, by diagnosis, is categorized into the pelvic examination, transvaginal ultrasound, and blood tests. Blood tests are further sub-divided into hormone levels, glucose tolerance and cholesterol and triglyceride levels. On the basis of treatment, the market is segmented into oral contraceptives, antiandrogens, insulin-sensitizing agents, antidepressant, anti-obesity, and surgery. The surgery category includes ovarian wedge resection and laparoscopic ovarian drilling. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and others.

On the basis of region, the global polycystic ovarian syndrome market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-divided into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-
segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

**Key players**


**Regional Market Summary**

**Global Polycystic Ovarian Syndrome Market Share (%), by Region, 2017**

![Pie chart showing market share by region]

Sources: Center for Disease Control and Prevention, Office on Women’s Health, Office of the Assistant Secretary for Health, US Department of Health and Human Services.

The polycystic ovarian syndrome market is dominated by North America owing to the rising obesity. According to the Institute for Health Metrics and Evaluation (IHME), 60% of women were obese or overweight in 2013. Other factors such as increasing healthcare expenditure, increasing technological advancements, and adoption of minimally invasive surgeries drive the market growth in this region.

It is estimated that Europe was the second largest in the global polycystic ovarian syndrome market owing to the increasing prevalence of diabetes, obesity, and increasing research activities in the health industry in this region. According to the German Federal Ministry of Health in 2014 and 2015, 7.0% of women of age 18 and more suffered from diabetes in Germany. Thus, the increasing prevalence of diabetes in this region influences the growth of this market in this region.

Asia-Pacific was projected to be the fastest growing region for the global polycystic ovarian syndrome market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. This provides favorable backgrounds for the market to grow.

The Middle East and Africa holds the least share in the global polycystic ovarian syndrome market due to the presence of stringent government policies and poor economies. However, the market is expected to witness growth due to the rising healthcare expenditure, growing private sector in the healthcare domain, and insurance coverage in the Middle East.

**Market Segmentation and Key Market Players**

**Global Polycystic Ovarian Syndrome Market, by Diagnosis**

- Pelvic examination
- Transvaginal ultrasound
- Blood tests
  - Hormone levels
- Glucose tolerance
- Cholesterol and triglyceride levels

**Global Polycystic Ovarian Syndrome Market, by Treatment**
- Oral Contraceptives
- Antiandrogens
- Insulin Sensitizing Agent
- Antidepressant
- Anti-Obesity
- Surgery
  - Ovarian Wedge Resection
  - Laparoscopic Ovarian Drilling

**Global Polycystic Ovarian Syndrome Market, by End-User**
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Diagnostic Centers
- Gynecology Centers
- Feminist Health Centers

**Global Polycystic Ovarian Syndrome Market, by Region**
- Americas
- Europe
- Asia-Pacific
- Middle East & Africa

**Intended Audience**
- Pharmaceutical companies
- Biotechnological institutes
- Government and private laboratories
- Research and Development (R&D) companies
- Medical research laboratories
- Market research and consulting service providers

**Contents:**

<table>
<thead>
<tr>
<th>TABLE OF CONTENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHAPTER 1. REPORT PROLOGUE</td>
</tr>
<tr>
<td>CHAPTER 2. MARKET INTRODUCTION</td>
</tr>
<tr>
<td>2.1 DEFINITION</td>
</tr>
<tr>
<td>2.2 SCOPE OF THE STUDY</td>
</tr>
<tr>
<td>2.2.1 RESEARCH OBJECTIVE</td>
</tr>
<tr>
<td>2.2.2 ASSUMPTIONS</td>
</tr>
<tr>
<td>2.2.3 LIMITATIONS</td>
</tr>
<tr>
<td>CHAPTER 3. RESEARCH METHODOLOGY</td>
</tr>
<tr>
<td>3.1 INTRODUCTION</td>
</tr>
<tr>
<td>3.2 PRIMARY RESEARCH</td>
</tr>
<tr>
<td>3.3 SECONDARY RESEARCH</td>
</tr>
<tr>
<td>3.4 MARKET SIZE ESTIMATION</td>
</tr>
<tr>
<td>CHAPTER 4. MARKET DYNAMICS</td>
</tr>
<tr>
<td>4.1 DRIVERS</td>
</tr>
<tr>
<td>4.2 RESTRAINTS</td>
</tr>
<tr>
<td>4.3 OPPORTUNITIES</td>
</tr>
<tr>
<td>4.4 CHALLENGES</td>
</tr>
<tr>
<td>4.5 MACROECONOMIC INDICATORS</td>
</tr>
</tbody>
</table>
CHAPTER 5. MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES ANALYSIS

5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF RIVALRY

5.2 VALUE CHAIN ANALYSIS
5.3 INVESTMENT FEASIBILITY ANALYSIS
5.4 PRICING ANALYSIS

CHAPTER 6. GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS

6.1 INTRODUCTION
6.2 PELVIC EXAMINATION
6.3 TRANSVAGINAL ULTRASOUND
6.4 BLOOD TESTS
6.4.1 HORMONE LEVELS
6.4.2 GLUCOSE TOLERANCE
6.4.3 CHOLESTEROL AND TRIGLYCERIDE LEVELS

7. GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT

7.1 INTRODUCTION
7.2 ORAL CONTRACEPTIVES
7.3 ANTIANDROGENS
7.4 INSULIN SENSITIZING AGENT
7.5 ANTIDEPRESSANT
7.6 ANTI-OBEITY
7.7 SURGERY
7.7.1 OVARIAN WEDGE RESECTION
7.7.2 LAPAROSCOPIC OVARIAN DRILLING

CHAPTER 8. GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER

8.1 INTRODUCTION
8.2 HOSPITALS & CLINICS
8.3 AMBULATORY SURGICAL CENTERS
8.4 DIAGNOSTIC CENTERS
8.5 GYNECOLOGY CENTERS
8.6 FEMINIST HEALTH CENTERS

CHAPTER 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY REGION

9.1 INTRODUCTION
9.2 AMERICA
9.2.1 NORTH AMERICA
9.2.1.1 US
9.2.1.2 CANADA
9.2.2 SOUTH AMERICA
9.3 EUROPE
9.3.1 WESTERN EUROPE
9.3.1.1 GERMANY
9.3.1.2 FRANCE
9.3.1.3 ITALY
9.3.1.4 SPAIN
9.3.1.5 UK
9.3.1.6 REST OF WESTERN EUROPE
9.3.2 EASTERN EUROPE
9.4 ASIA-PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 AUSTRALIA
9.4.5 REPUBLIC OF KOREA
9.4.6 REST OF ASIA-PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 UNITED ARAB EMIRATES
9.5.2 SAUDI ARABIA
9.5.3 OMAN
9.5.4 KUWAIT
9.5.5 QATAR
9.5.6 REST OF THE MIDDLE EAST & AFRICA

CHAPTER 10. COMPANY LANDSCAPE
10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS
10.3 KEY DEVELOPMENT & STRATEGIES
10.3.1 KEY DEVELOPMENTS

CHAPTER 11 COMPANY PROFILES
11.1 BAYER AG
11.1.1 COMPANY OVERVIEW
11.1.2 TYPE OVERVIEW
11.1.3 FINANCIALS
11.2.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.2 ASTRazeneca PLC
11.2.1 COMPANY OVERVIEW
11.2.2 TYPE OVERVIEW
11.2.3 FINANCIAL OVERVIEW
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.3 ABBOTT
11.3.1 COMPANY OVERVIEW
11.3.2 TYPE OVERVIEW
11.3.3 FINANCIAL OVERVIEW
11.3.4 KEY DEVELOPMENT
11.3.5 SWOT ANALYSIS
11.4 BIOCINESE
11.4.1 COMPANY OVERVIEW
11.4.2 TYPE/BUSINESS SEGMENT OVERVIEW
11.4.3 FINANCIAL OVERVIEW
11.4.4 KEY DEVELOPMENT
11.4.5 SWOT ANALYSIS
11.13 NEUROCRINE BIOSCIENCES
11.13.1 OVERVIEW
11.13.2 TYPE OVERVIEW
11.13.3 FINANCIALS
11.13.4 KEY DEVELOPMENTS
11.13.5 SWOT ANALYSIS
11.14 RELIANCE LIFE SCIENCES PVT. LTD
11.14.1 OVERVIEW
11.14.2 TYPE OVERVIEW
11.14.3 FINANCIALS
11.14.4 KEY DEVELOPMENTS
11.14.5 SWOT ANALYSIS
11.15 PFIZER, INC
11.15.1 OVERVIEW
11.15.2 TYPE OVERVIEW
11.15.3 FINANCIALS
11.15.4 KEY DEVELOPMENTS
11.15.5 SWOT ANALYSIS
11.15 OTHERS

CHAPTER 12 APPENDIX

LIST OF TABLES

TABLE 1 POLYCYSTIC OVARIAN SYNDROME MARKET INDUSTRY SYNOPSIS, 2018–2023
TABLE 2 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET ESTIMATES & FORECAST, 2018–2023, (USD MILLION)
TABLE 3 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY REGION, 2018–2023, (USD MILLION)
TABLE 4 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2018–2023, (USD MILLION)
TABLE 5 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2018–2023, (USD MILLION)
TABLE 6 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2018–2023, (USD MILLION)
TABLE 7 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2018–2023, (USD MILLION)
TABLE 8 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2018–2023, (USD MILLION)
TABLE 9 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2018–2023, (USD MILLION)
TABLE 10 US POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2018–2023, (USD MILLION)
TABLE 11 US POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2018–2023, (USD MILLION)
TABLE 12 US POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2018–2023, (USD MILLION)
TABLE 13 CANADA POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2018–2023, (USD MILLION)
TABLE 14 CANADA POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2018–2023, (USD MILLION)
TABLE 15 CANADA POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2018–2023, (USD MILLION)
TABLE 16 SOUTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2018–2023, (USD MILLION)
TABLE 17 SOUTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2018–2023, (USD MILLION)
TABLE 18 SOUTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2018–2023, (USD MILLION)
TABLE 19 EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, DIAGNOSIS, 2018–2023, (USD MILLION)
TABLE 20 EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2018–2023, (USD MILLION)
TABLE 21 EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2018–2023, (USD MILLION)
TABLE 22 WESTERN EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2018–2023,
FIGURE 29 CATALYSIS: SEGMENTAL REVENUE
FIGURE 30 CATALYSIS: GEOGRAPHICAL REVENUE
FIGURE 31 SANOFI: KEY FINANCIALS
FIGURE 32 SANOFI: SEGMENTAL REVENUE
FIGURE 33 SANOFI: GEOGRAPHICAL REVENUE
FIGURE 34 EUGONIA: KEY FINANCIALS
FIGURE 35 EUGONIA: SEGMENTAL REVENUE
FIGURE 36 EUGONIA: GEOGRAPHICAL REVENUE
FIGURE 37 EFFRX, INC.: KEY FINANCIALS
FIGURE 38 EFFRX, INC.: SEGMENTAL REVENUE
FIGURE 39 EFFRX, INC.: GEOGRAPHICAL REVENUE
FIGURE 40 FERRING PHARMACEUTICALS, INC: KEY FINANCIALS
FIGURE 41 FERRING PHARMACEUTICALS, INC: SEGMENTAL REVENUE
FIGURE 42 FERRING PHARMACEUTICALS, INC: GEOGRAPHICAL REVENUE
FIGURE 46 BRISTOL-MYER SQUIBB COMPANY: KEY FINANCIALS
FIGURE 47 BRISTOL-MYER SQUIBB COMPANY: SEGMENTAL REVENUE
FIGURE 48 BRISTOL-MYER SQUIBB COMPANY: GEOGRAPHICAL REVENUE
FIGURE 49 NEUROCRINE BIOSCIENCES: KEY FINANCIALS
FIGURE 50 NEUROCRINE BIOSCIENCES: SEGMENTAL REVENUE
FIGURE 51 NEUROCRINE BIOSCIENCES: GEOGRAPHICAL REVENUE
FIGURE 52 C.R. BARD: KEY FINANCIALS
FIGURE 53 C.R. BARD: SEGMENTAL REVENUE
FIGURE 54 C.R. BARD: GEOGRAPHICAL REVENUE
FIGURE 55 RELIANCE LIFE SCIENCES PVT. LTD: KEY FINANCIALS
FIGURE 56 RELIANCE LIFE SCIENCES PVT. LTD: SEGMENTAL REVENUE
FIGURE 57 RELIANCE LIFE SCIENCES PVT. LTD: GEOGRAPHICAL REVENUE
FIGURE 58 PFIZER, INC: KEY FINANCIALS
FIGURE 59 PFIZER, INC: SEGMENTAL REVENUE
FIGURE 60 PFIZER, INC: GEOGRAPHICAL REVENUE